News Posts List
The development of squamous cell carcinoma in a patient after kidney transplantation
01/31/2014
In patients with organ transplantation as compared to the general population the risk of cancer is significantly increased.
ASIs Improve Survival: News from 2014 ASCO GU
01/31/2014
Common drug may improve kidney cancer survival.
AGS-003 Clinical Trail Update
01/30/2014
A trial-in-progress update on AGS-003 from the 2014 ASCO GU meeting in San Francisco.
Outcome predicted by early tumor response from stereotactic radiosurgery
01/30/2014
"We could eventually predict for individual patients before we treat them what the likelihood is that they would respond," said Dr. Ewend.
Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma
01/29/2014
This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy.
Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium
01/29/2014
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).
Early tumor response from stereotactic radiosurgery predicts outcom
01/28/2014
The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.
FDG-PET as a predictive biomarker
01/28/2014
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.
News Feed